Calliditas Therapeutics announces USPTO issues patent for setanaxib

Calliditas Therapeutics announced that the United States Patent and Trademark Office has issued a patent for application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer.” The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent will have an expiration date in 2039. Calliditas has corresponding applications and patents in several additional territories around the world, including a pending patent application in Europe. Calliditas read out positive topline results of its Phase 2 head and neck cancer trial with setanaxib in May 2024. The analysis showed statistically significant improvements in progression-free survival, as well as in overall survival, with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib.